Compare Crocs, Inc. (CROX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Crocs (CROX) trades at $114.98, down 0.19% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong Q2 2026 EPS of $4.55, beating expectations by $0.20, but faces challenges with a negative net income of -$81.20M for 2025. Valuation metrics remain attractive with a P/E of 10.37 and P/S of 1.48, while analyst consensus leans bullish with a $136.78 price target representing 19% upside potential.

CROX presents a mixed investment case with compelling valuation and strong brand positioning offset by recent profitability concerns. The key opportunity lies in the company's product innovation and HEYDUDE brand reset, while risks include consumer spending volatility and execution challenges. With 51% of analysts maintaining buy ratings, the stock offers potential upside if management can restore consistent profitability growth.

Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.

The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.